LM303 injection for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma, non-small cell lung cancer, cervical cancer, or another solid tumor that hasn't responded to standard treatments or has no standard treatment.
- You have at least one tumor that is large enough (more than 1.5 cm³) to be surgically removed or biopsied for TIL collection.
- Your blood counts must be within certain ranges, including enough white blood cells and lymphocytes (a type of immune cell).
- Your liver and kidney function must be adequate, and your heart must pump at least 50% of blood with each beat.
- You must be in good daily health (ECOG score 0 or 1) and expected to live more than 3 months.
- You cannot have active autoimmune disease, uncontrolled infections, or certain viruses like hepatitis or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
This early-stage trial tests a type of immune cell treatment (TILs) made from your tumor to treat advanced solid cancers. It may help if standard treatments have failed or aren’t an option, but you must be able to provide enough tumor tissue for cell collection.
This early-phase study tests LM103 in people with advanced solid cancers that have not responded to standard treatments or where standard options are not suitable. It mainly focuses on whether LM103 can be safely given and whether it can shrink tumors or help control the disease.
This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.